carnitine has been researched along with Ischemia in 33 studies
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Propionyl-L-carnitine (PLC) is efficacious in improving pain free walking distance in peripheral arterial disease with claudication; it also exerts favorable effects on the arterial wall and on endothelial function." | 9.16 | Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. ( Arosio, E; De Marchi, S; Fondrieschi, L; Prior, M; Rigoni, A; Rulfo, F; Scuro, A; Zecchetto, S, 2012) |
| "To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines." | 9.14 | Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009) |
| "Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication." | 7.81 | Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015) |
| "To investigate the protective effects of L-carnitine upon testicular ischemia-reperfusion injury in rats." | 7.75 | [Protective effects of L-carnitine upon testicular ischemia-reperfusion damage in rats]. ( Guan, Y; Li, SW; Yang, ZW; Zheng, XM, 2009) |
| "The study aimed to examine whether L-carnitine and its derivatives, acetyl-L-carnitine and propionyl-L-carnitine, were equally effective and able to improve postischemic cardiac function, reduce the incidence of reperfusion-induced ventricular fibrillation, infarct size, and apoptotic cell death in ischemic/reperfused isolated rat hearts." | 7.72 | Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. ( Bertelli, A; Cui, J; Das, DK; Tosaki, A, 2003) |
| "The present study was designed to examine whether propionyl-l-carnitine, an acyl derivative of carnitine involved in fatty acid oxidation pathway and adenosine 5'-triphosphate (ATP) generation of mitochondria, prevented renal function deterioration and structural injury induced by ischemia-reperfusion in an ex vivo rat model of isolated perfused kidney (IPK) preparation and in vivo in a model of syngeneic kidney transplantation." | 7.71 | Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. ( Abbate, M; Aiello, S; Arduini, A; Azzollini, N; Gagliardini, E; Mister, M; Noris, M; Perico, N; Remuzzi, G; Szymczuk, J; Trochimowicz, L, 2002) |
| "In this study we have examined the effect of propionyl-L-carnitine (PC) on rat spinal cord ischaemia and post-ischaemic reperfusion injury by evaluating two lipid peroxidation indices, thiobarbituric acid reactive substances (TBARS) and diene conjugation, before and after the addition of an ADP-Fe+2 complex to spinal cord homogenates." | 7.68 | Effect of propionyl-L-carnitine on rat spinal cord ischaemia and post-ischaemic reperfusion injury. ( Arduini, A; Belfiglio, M; Di Toppi, GS; Federici, G; Fernandez, E; Mancinelli, G; Pallini, R; Scurti, R, 1990) |
| "L-carnitine treatment reduced these parameters to the values of sham operated rats." | 5.32 | L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation. ( Agac, A; Aliciguzel, Y; Demir, N; Derin, N; Izgut-Uysal, VN, 2004) |
| " Propionyl-L-carnitine (PLC) is efficacious in improving pain free walking distance in peripheral arterial disease with claudication; it also exerts favorable effects on the arterial wall and on endothelial function." | 5.16 | Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. ( Arosio, E; De Marchi, S; Fondrieschi, L; Prior, M; Rigoni, A; Rulfo, F; Scuro, A; Zecchetto, S, 2012) |
| "To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines." | 5.14 | Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009) |
| "Propionyl-L-carnitine (PrC) has been shown to exert beneficial effects in the treatment of myocardial and peripheral ischemia in man." | 5.09 | Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine. ( Battaglia, C; Brevetti, G; Gentile, M; Golino, P; Marone, G; Oriente, A; Triggiani, M, 1999) |
| "Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication." | 3.81 | Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015) |
| "To investigate the protective effects of L-carnitine upon testicular ischemia-reperfusion injury in rats." | 3.75 | [Protective effects of L-carnitine upon testicular ischemia-reperfusion damage in rats]. ( Guan, Y; Li, SW; Yang, ZW; Zheng, XM, 2009) |
| "Carnitine has a positive effect in such a model, particularly in preventing the progressive effect of burn, and limiting the necrosis in the full-thickness burned part." | 3.72 | The effects of carnitine on distally-burned dorsal skin flap: an experimental study in rats. ( Aksoy, A; Arslan, E; Bagdatoglu, O; Demirkan, F; Milcan, A; Polat, A; Polat, G; Unal, S, 2003) |
| "The study aimed to examine whether L-carnitine and its derivatives, acetyl-L-carnitine and propionyl-L-carnitine, were equally effective and able to improve postischemic cardiac function, reduce the incidence of reperfusion-induced ventricular fibrillation, infarct size, and apoptotic cell death in ischemic/reperfused isolated rat hearts." | 3.72 | Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. ( Bertelli, A; Cui, J; Das, DK; Tosaki, A, 2003) |
| "L-carnitine represents a feasible metabolic adjunct for a safe and more successful preservation of ischemia-reperfusion-sensitive steatotic livers." | 3.72 | L-carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation. ( Decker, D; Dombrowski, F; Lauschke, H; Pütz, U; Tolba, RH, 2003) |
| " We investigated whether sodium bicarbonate-induced metabolic alkalosis could positively affect force development during the rest-to-work transition in ischaemic skeletal muscle." | 3.71 | Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle. ( Constantin-Teodosiu, D; Greenhaff, PL; Loxham, SJ; Poucher, SM; Roberts, PA, 2002) |
| "The present study was designed to examine whether propionyl-l-carnitine, an acyl derivative of carnitine involved in fatty acid oxidation pathway and adenosine 5'-triphosphate (ATP) generation of mitochondria, prevented renal function deterioration and structural injury induced by ischemia-reperfusion in an ex vivo rat model of isolated perfused kidney (IPK) preparation and in vivo in a model of syngeneic kidney transplantation." | 3.71 | Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. ( Abbate, M; Aiello, S; Arduini, A; Azzollini, N; Gagliardini, E; Mister, M; Noris, M; Perico, N; Remuzzi, G; Szymczuk, J; Trochimowicz, L, 2002) |
| "We have characterized the effects of hypoxia on carnitine metabolism in proximal tubules." | 3.69 | Hypoxia-induced amphiphiles inhibit renal Na+, K(+)-ATPase. ( Bertorello, AM; Creer, MH; Mandel, LJ; Noble, S; Portilla, D; Schonefeld, M, 1996) |
| "In this study we have examined the effect of propionyl-L-carnitine (PC) on rat spinal cord ischaemia and post-ischaemic reperfusion injury by evaluating two lipid peroxidation indices, thiobarbituric acid reactive substances (TBARS) and diene conjugation, before and after the addition of an ADP-Fe+2 complex to spinal cord homogenates." | 3.68 | Effect of propionyl-L-carnitine on rat spinal cord ischaemia and post-ischaemic reperfusion injury. ( Arduini, A; Belfiglio, M; Di Toppi, GS; Federici, G; Fernandez, E; Mancinelli, G; Pallini, R; Scurti, R, 1990) |
| "Carnitine is an endogenous cofactor, having a regulatory action on the energy flow from different oxidative sources." | 1.38 | Comparing the effect between oral and injection form of carnitine on skin flap survival in rats. ( Lawanlakkana, P; Pitiseree, A; Saraithong, S; Suwantemee, C, 2012) |
| "L-carnitine treatment reduced these parameters to the values of sham operated rats." | 1.32 | L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation. ( Agac, A; Aliciguzel, Y; Demir, N; Derin, N; Izgut-Uysal, VN, 2004) |
| "Carnitine is an endogenous cofactor, for having a regulatory action on the energy flow from different oxidative sources." | 1.32 | Dual synergistic effect: the effect of dexamethasone plus carnitine on skin flap survival. ( Babuccu, O; Deren, O; Erdogan, B; Hosnuter, M; Kargi, E, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 11 (33.33) | 18.2507 |
| 2000's | 13 (39.39) | 29.6817 |
| 2010's | 6 (18.18) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Liepinsh, E | 1 |
| Kuka, J | 1 |
| Vilks, K | 1 |
| Svalbe, B | 1 |
| Stelfa, G | 1 |
| Vilskersts, R | 1 |
| Sevostjanovs, E | 1 |
| Goldins, NR | 1 |
| Groma, V | 1 |
| Grinberga, S | 1 |
| Plaas, M | 1 |
| Makrecka-Kuka, M | 1 |
| Dambrova, M | 1 |
| Moghaddas, A | 1 |
| Dashti-Khavidaki, S | 1 |
| Shiga, T | 1 |
| Sahara, H | 1 |
| Orito, K | 1 |
| Milio, G | 1 |
| Novo, G | 1 |
| Genova, C | 1 |
| Luigi Almasio, P | 1 |
| Novo, S | 1 |
| Pinto, A | 1 |
| Guan, Y | 1 |
| Zheng, XM | 1 |
| Yang, ZW | 1 |
| Li, SW | 1 |
| Stasi, MA | 1 |
| Scioli, MG | 1 |
| Arcuri, G | 1 |
| Mattera, GG | 1 |
| Lombardo, K | 1 |
| Marcellini, M | 1 |
| Riccioni, T | 1 |
| De Falco, S | 1 |
| Pisano, C | 1 |
| Spagnoli, LG | 1 |
| Borsini, F | 1 |
| Orlandi, A | 1 |
| Riccioni, C | 1 |
| Sarcinella, R | 1 |
| Izzo, A | 1 |
| Palermo, G | 1 |
| Liguori, M | 1 |
| Caliumi, C | 1 |
| Carloni, E | 1 |
| Paolucci, AM | 1 |
| D'andrea, P | 1 |
| Pompili, S | 1 |
| Lawanlakkana, P | 1 |
| Saraithong, S | 1 |
| Suwantemee, C | 1 |
| Pitiseree, A | 1 |
| De Marchi, S | 1 |
| Zecchetto, S | 1 |
| Rigoni, A | 1 |
| Prior, M | 1 |
| Fondrieschi, L | 1 |
| Scuro, A | 1 |
| Rulfo, F | 1 |
| Arosio, E | 1 |
| Roberts, PA | 2 |
| Loxham, SJ | 2 |
| Poucher, SM | 3 |
| Constantin-Teodosiu, D | 3 |
| Greenhaff, PL | 3 |
| Arslan, E | 1 |
| Milcan, A | 1 |
| Unal, S | 1 |
| Demirkan, F | 1 |
| Polat, A | 1 |
| Bagdatoglu, O | 1 |
| Aksoy, A | 1 |
| Polat, G | 1 |
| Cui, J | 1 |
| Das, DK | 1 |
| Bertelli, A | 1 |
| Tosaki, A | 1 |
| Tolba, RH | 2 |
| Pütz, U | 1 |
| Decker, D | 1 |
| Dombrowski, F | 2 |
| Lauschke, H | 1 |
| Hiatt, WR | 1 |
| Derin, N | 1 |
| Izgut-Uysal, VN | 1 |
| Agac, A | 1 |
| Aliciguzel, Y | 1 |
| Demir, N | 1 |
| Kargi, E | 1 |
| Deren, O | 1 |
| Babuccu, O | 1 |
| Hosnuter, M | 1 |
| Erdogan, B | 1 |
| Vavilin, VA | 1 |
| Filippova, SN | 1 |
| Panov, AV | 1 |
| Levandovskiĭ, IV | 1 |
| Stevens, MJ | 1 |
| Feldman, EL | 1 |
| Greene, DA | 1 |
| Corsi, C | 1 |
| Pollastri, M | 1 |
| Marrapodi, E | 1 |
| Leanza, D | 1 |
| Giordano, S | 1 |
| D'Iddio, S | 1 |
| Peschechera, A | 1 |
| Ferrari, LE | 1 |
| Arrigoni-Martelli, E | 1 |
| Hülsmann, WC | 1 |
| Timmons, JA | 1 |
| Worrall, V | 1 |
| Macdonald, IA | 1 |
| Schonefeld, M | 1 |
| Noble, S | 1 |
| Bertorello, AM | 1 |
| Mandel, LJ | 1 |
| Creer, MH | 1 |
| Portilla, D | 1 |
| Nagai, M | 1 |
| Watanabe, M | 1 |
| Endoh, M | 1 |
| Danbara, H | 1 |
| Triggiani, M | 1 |
| Oriente, A | 1 |
| Golino, P | 1 |
| Gentile, M | 1 |
| Battaglia, C | 1 |
| Brevetti, G | 3 |
| Marone, G | 1 |
| Scarpini, E | 1 |
| Doneda, P | 1 |
| Pizzul, S | 1 |
| Chiodi, P | 1 |
| Ramacci, MT | 1 |
| Baron, P | 1 |
| Conti, G | 1 |
| Sacilotto, G | 1 |
| Arduini, A | 3 |
| Scarlato, G | 1 |
| Puetz, U | 1 |
| Akbar, S | 1 |
| Minor, T | 1 |
| Signorelli, SS | 1 |
| Malaponte, G | 1 |
| Di Pino, L | 1 |
| Digrandi, D | 1 |
| Pennisi, G | 1 |
| Mazzarino, MC | 1 |
| Mister, M | 1 |
| Noris, M | 1 |
| Szymczuk, J | 1 |
| Azzollini, N | 1 |
| Aiello, S | 1 |
| Abbate, M | 1 |
| Trochimowicz, L | 1 |
| Gagliardini, E | 1 |
| Perico, N | 1 |
| Remuzzi, G | 1 |
| Perna, S | 2 |
| Sabbà, C | 1 |
| Rossini, A | 1 |
| Scotto di Uccio, V | 1 |
| Berardi, E | 1 |
| Godi, L | 1 |
| Angelini, C | 1 |
| Rosa, M | 1 |
| Carrozzo, R | 1 |
| Corsi, M | 1 |
| Matarazzo, A | 1 |
| Marcialis, A | 1 |
| Fernandez, E | 1 |
| Pallini, R | 1 |
| Mancinelli, G | 1 |
| Di Toppi, GS | 1 |
| Belfiglio, M | 1 |
| Scurti, R | 1 |
| Federici, G | 1 |
| Pauly, DF | 1 |
| Yoon, SB | 1 |
| McMillin, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
3 reviews available for carnitine and Ischemia
| Article | Year |
|---|---|
L-Carnitine and Potential Protective Effects Against Ischemia-Reperfusion Injury in Noncardiac Organs: From Experimental Data to Potential Clinical Applications.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Female; Gastrointestinal Diseases; Human | 2018 |
Treatment of disability in peripheral arterial disease: new drugs.
Topics: Arteriosclerosis; Carnitine; Clinical Trials as Topic; Exercise Therapy; Humans; Hypolipidemic Agent | 2004 |
The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects.
Topics: Aldehyde Reductase; Animals; Carnitine; Cells; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 1995 |
6 trials available for carnitine and Ischemia
| Article | Year |
|---|---|
Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.
Topics: Aged; Alprostadil; Cardiotonic Agents; Carnitine; Chronic Disease; Double-Blind Method; Drug Synergi | 2009 |
Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Monitoring, Transcutaneo | 2012 |
L-propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease.
Topics: Aged; Blood Flow Velocity; Carnitine; Cross-Over Studies; Double-Blind Method; Humans; Hyperemia; In | 1995 |
Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine.
Topics: Adult; Arachidonic Acids; Blood Platelets; Cardiotonic Agents; Carnitine; Eicosanoids; Humans; In Vi | 1999 |
Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of L-propionyl carnitine administration.
Topics: Aged; Arteriosclerosis; Cardiotonic Agents; Carnitine; Cell Adhesion Molecules; Chronic Disease; E-S | 2001 |
Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study.
Topics: Arterial Occlusive Diseases; Carnitine; Dose-Response Relationship, Drug; Double-Blind Method; Exerc | 1992 |
24 other studies available for carnitine and Ischemia
| Article | Year |
|---|---|
Low cardiac content of long-chain acylcarnitines in TMLHE knockout mice prevents ischaemia-reperfusion-induced mitochondrial and cardiac damage.
Topics: Animals; Carnitine; Ischemia; Male; Mice; Mice, Knockout; Mitochondria, Heart; Reperfusion | 2021 |
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
Topics: Angiogenic Proteins; Animals; Carnitine; Cilostazol; Disease Models, Animal; Drug Therapy, Combinati | 2015 |
[Protective effects of L-carnitine upon testicular ischemia-reperfusion damage in rats].
Topics: Animals; Apoptosis; Carnitine; Heat-Shock Proteins; Ischemia; Male; Rats; Rats, Sprague-Dawley; Repe | 2009 |
Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Carnitine; Cell Proliferation; Chic | 2010 |
Rehabilitative treatment in peripheral artery disease: protocol application and follow-up.
Topics: Aged; Cardiotonic Agents; Carnitine; Clinical Protocols; Combined Modality Therapy; Diabetes Mellitu | 2010 |
Comparing the effect between oral and injection form of carnitine on skin flap survival in rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Carnitine; Case-Control Studies; Graft Survival | 2012 |
The acetyl group deficit at the onset of contraction in ischaemic canine skeletal muscle.
Topics: Acetyl Coenzyme A; Acetylation; Animals; Carnitine; Coenzyme A; Dogs; Enzyme Activation; In Vitro Te | 2002 |
Bicarbonate-induced alkalosis augments cellular acetyl group availability and isometric force during the rest-to-work transition in canine skeletal muscle.
Topics: Acetylcarnitine; Alkalosis; Animals; Carnitine; Dogs; Electric Stimulation; Female; Infusions, Intra | 2002 |
The effects of carnitine on distally-burned dorsal skin flap: an experimental study in rats.
Topics: Acetylcholinesterase; Animals; Burns; Carnitine; Ischemia; Malondialdehyde; Necrosis; Nitric Oxide; | 2003 |
Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts.
Topics: Acetylcarnitine; Animals; Apoptosis; Cardiotonic Agents; Carnitine; Heart; Ischemia; Myocardium; Myo | 2003 |
L-carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation.
Topics: Alanine Transaminase; Animals; Carnitine; Fatty Liver; Glucose; Glutamate Dehydrogenase; Ischemia; L | 2003 |
L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation.
Topics: Animals; Carnitine; Catalase; Dinoprostone; Gastric Mucosa; Glutathione Peroxidase; Glycosaminoglyca | 2004 |
Dual synergistic effect: the effect of dexamethasone plus carnitine on skin flap survival.
Topics: Animals; Carnitine; Dexamethasone; Drug Synergism; Ischemia; Rats; Rats, Sprague-Dawley; Surgical Fl | 2004 |
[Mechanisms of disruption of mitochondrial transport of adenine nucleotides in the course of acute hepatic ischemia].
Topics: Acute Disease; Acyl Coenzyme A; Adenine Nucleotides; Animals; Carnitine; Female; Ischemia; Ketogluta | 1980 |
Uptake and release of carnitine by vascular endothelium in culture; effects of protons and oxygen free radicals.
Topics: Acidosis; Animals; Carnitine; Cattle; Cell Membrane; Cells, Cultured; Endothelium, Vascular; Female; | 1995 |
Increased acetyl group availability enhances contractile function of canine skeletal muscle during ischemia.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aerobiosis; Anaerobiosis; Animals; Carbohydrate Metabolism; | 1996 |
Hypoxia-induced amphiphiles inhibit renal Na+, K(+)-ATPase.
Topics: Animals; Carnitine; Dogs; Fatty Acids; Hypoxia; In Vitro Techniques; Ischemia; Kidney; Kidney Tubule | 1996 |
Inhibitory effect of acyl-CoA and acyl-carnitine compounds on the ischemia-inducing activity of Bordetella heat-labile toxin in guinea pig skin.
Topics: Acyl Coenzyme A; Animals; Bacterial Toxins; Bordetella; Carnitine; Fatty Acids, Unsaturated; Guinea | 1997 |
L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Carnitine; Diabetic Neuropathies; Female; Humans; I | 1996 |
Effects of L-carnitine-hydrochloride in the cold ischemic preservation of fatty liver grafts.
Topics: Animals; Carnitine; Cold Temperature; Fatty Liver; Glucose; Ischemia; L-Lactate Dehydrogenase; Liver | 2001 |
Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion.
Topics: Animals; Carnitine; In Vitro Techniques; Ischemia; Kidney; Kidney Transplantation; Male; Rats; Rats, | 2002 |
Muscle carnitine deficiency in patients with severe peripheral vascular disease.
Topics: Aged; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransferase; Humans; Ischemia; | 1991 |
Effect of propionyl-L-carnitine on rat spinal cord ischaemia and post-ischaemic reperfusion injury.
Topics: Animals; Carnitine; Free Radicals; In Vitro Techniques; Ischemia; Lipid Peroxidation; Male; Rats; Ra | 1990 |
Carnitine-acylcarnitine translocase in ischemia: evidence for sulfhydryl modification.
Topics: Animals; Biological Transport; Carnitine; Carnitine Acyltransferases; Carnitine O-Palmitoyltransfera | 1987 |